Welcome to our dedicated page for ABPRO HLDGS SEC filings (Ticker: ABP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Abpro Holdings filings document a clinical-stage biotechnology issuer with Nasdaq-listed common stock and warrants, emerging growth company status, and regulatory disclosures for its antibody therapeutics business. Form 8-K reports cover FDA IND submission and clearance disclosures for ABP-102/CT-P72, material agreements, Nasdaq listing-rule matters, and board and committee changes.
Registration statements describe securities offerings and capital structure, including common stock and warrants. Periodic-report notices and late-filing forms address annual reporting obligations, while material-event filings provide formal records of governance, financing, operating, and public-company compliance matters.
Abpro Holdings, Inc. reports that it has failed to regain compliance with Nasdaq’s minimum bid price requirement of $1.00 per share by the September 29, 2025 deadline. On September 30, 2025, Nasdaq notified the company that its common stock is subject to delisting.
Unless Abpro appeals by October 7, 2025, its common stock would be scheduled for delisting at the opening of business on October 9, 2025. The company plans to request a hearing before a Nasdaq appeal panel, which will temporarily keep its securities trading while the panel reviews its plans to regain compliance.
Abpro cautions that there is no assurance the panel will grant continued listing or that it will meet all Nasdaq requirements within any extension period that might be provided.
Abpro Holdings, Inc. disclosed that its Chief Medical Officer, Dr. Robert J. Markelewicz, Jr., M.D., M.M.Sc., has been furloughed and will be leaving the company. Effective September 30, 2025, the company placed him on furlough through November 30, 2025, during which he will not perform any duties or responsibilities associated with his role. The filing states that his employment will be terminated effective November 30, 2025, signaling a planned transition away from this key executive position.